Endocrine Disorders

📚 03 Neonatology • 🎯 25 High-Yield MCQs • Nelson 22nd Edition Standard

Fetal and Neonatal Thyroid Physiology & Transplacental Transfer

  • Maternal-Fetal Thyroid Dynamics & Hypothyroxinemia: ((NEND001)): Maternal TSH does not cross the placenta due to large molecular size. Thyroxine (T4) and triiodothyronine (T3) cross in limited amounts because they are inactivated by placental type 3 deiodinase (converting T4 to inactive reverse T3). In fetal hypothyroxinemia, a compensatory increase in maternal-to-fetal transfer of T4 occurs in the second and third trimesters to protect the fetus.
  • Preterm Neonatal Thyroid Physiology: ((NEND002)): Compared to term infants, preterm infants (especially <31 weeks) exhibit a blunted TSH surge with a reduced rise in T4 and T3 levels due to hypothalamic-pituitary-thyroid axis immaturity.
  • Congenital Hypothyroidism Screening in Preterm Infants: ((NEND006)): Infants with birth weight <1500 g require repeat screening at 2, 6, and 10 weeks of age regardless of initial results due to delayed TSH elevation risk.

Congenital Hypothyroidism: Etiology, Genetics, and Diagnosis

  • Genetics of Thyroid Dysgenesis: ((((NEND003)) · ((NEND004)))): Thyroid dysgenesis (agenesis, hypoplasia, ectopy) is predominantly sporadic (low recurrence risk). Candidate transcription factor mutations include PAX8, FOXE1, NKX2.1, and NKX2.5. GNAS (encoding Gs$\alpha$ protein, associated with pseudohypoparathyroidism) is not involved in thyroid embryogenesis.
  • TSH Receptor Resistance: ((NEND005)): Persistent hyperthyrotropinemia with low-normal free T4 and a small, normally located gland without goiter indicates TSH receptor mutations (impaired receptor signaling).
  • Thyroid Hypoplasia vs. Dyshormonogenesis: ((NEND016)): Low serum thyroglobulin with detectable thyroid tissue favors thyroid hypoplasia. Conversely, dyshormonogenesis typically presents with goiter and elevated thyroglobulin levels.
  • Iodine-Induced Hypothyroidism: ((NEND017)): Preterm neonates exposed to excess iodine develop primary hypothyroidism via the Wolff-Chaikoff effect, characterized by a normal-sized gland, elevated thyroglobulin, and high urinary iodine.
  • Central Hypothyroidism & Pituitary Evaluation: ((NEND018)): Low T4 with inappropriately normal/low TSH, hypoglycemia, micropenis, and midline facial defects indicates central hypothyroidism. Mandatory action: Measure serum cortisol and growth hormone levels before starting L-thyroxine to avoid precipitating an adrenal crisis.
  • Transient Hypothyroxinemia of Prematurity: ((((NEND007)) · ((NEND019)))): Extremely low birth weight/critically ill infants may present with delayed TSH elevation. Initial newborn screens can be falsely normal. Treatment monitoring requires T4 normalization within 1 week and TSH within 2 weeks of starting therapy; first follow-up FT4 at 1–2 weeks, and assessments every 1–3 months during the first year of life.

Maternal Thyroid Disease in Pregnancy & Neonatal Management

  • Hyperthyroidism in Pregnancy & Antithyroid Drugs: ((((NEND008)) · ((NEND011)) · ((NEND012)))): - First trimester: Propylthiouracil (PTU) is preferred over methimazole to avoid embryopathy (cutis aplasia). - Second trimester onwards: Switch to methimazole because PTU carries a high risk of severe maternal hepatotoxicity. - In cases of agranulocytosis/complications requiring discontinuation of antithyroid drugs, surgical thyroidectomy in the second trimester is the definitive therapy. Radioactive iodine is strictly contraindicated in pregnancy.
  • Fetal Graves' Disease & Surveillance: ((((NEND013)) · ((NEND014)))): Transplacental TSH receptor-stimulating antibodies can cause fetal hyperthyroidism independently of maternal thyroid control. Surveillance requires serial fetal heart rate monitoring and ultrasound for fetal goiter. Neonates born to mothers with Graves' disease treated with antithyroid drugs may show transient neonatal thyrotoxicosis (as maternal drugs wash out in days 1–4) followed by neonatal hypothyroidism as maternal antibodies clear.
  • Trimester-Specific TSH Ranges: ((NEND015)): Maternal hypothyroidism screening utilizes trimester-specific TSH reference ranges (first trimester: 0.1–2.5 mIU/L; second: 0.2–3.0 mIU/L; third: 0.3–3.0 mIU/L).

Gestational Diabetes Mellitus (GDM) & Fetal Growth

  • GDM Risk Factors & Fetal Monitoring: ((((NEND009)) · ((NEND020)))): - Risk factors include advanced maternal age, multiparity, short stature, and multifetal gestation (younger maternal age is not a risk factor). - Fetal abdominal circumference (AC) >70th percentile after 29–30 weeks indicates fetal hyperinsulinemia and disproportionate macrosomia despite borderline maternal glycemic control, mandating escalation to insulin therapy.

Disorders of Sex Development (DSD) & Ambiguous Genitalia

  • Timing of Hormonal Evaluation: ((NEND021)): Hormonal assays (17-OHP, LH, testosterone) in newborns with suspected DSD must be interpreted when obtained after 48–72 hours of life to avoid confounding by early postnatal hormonal surges.
  • 46,XY Complete Gonadal Dysgenesis (Swyer Syndrome): ((NEND022)): Defective SRY-mediated testicular differentiation leads to absent AMH and testosterone, persistent Müllerian structures (uterus), and a 46,XY karyotype. The risk of germ cell tumors reaches ~30%, requiring gonadectomy.
  • Androgen Synthesis Defects vs. Metabolism Defects: ((NEND023)): - Androgen synthesis defects (low testosterone, elevated precursors) include 17$\beta$-hydroxysteroid dehydrogenase, 3$\beta$-hydroxysteroid dehydrogenase, and 17$\alpha$-hydroxylase deficiencies. - 5$\alpha$-reductase deficiency is a defect in androgen metabolism (normal testosterone, impaired conversion to dihydrotestosterone).
  • Micropenis & Panhypopituitarism Management: ((NEND024)): Neonates presenting with micropenis, hypoglycemia, and panhypopituitarism require immediate intravenous hydrocortisone for life-threatening adrenal insufficiency before initiating testosterone or growth hormone therapy.
  • Evaluation Threshold for DSD: ((NEND025)): Any combination of cryptorchidism with proximal hypospadias or micropenis mandates a full DSD workup (karyotype and hormonal profile) regardless of electrolyte stability or normal initial imaging.